Strategy for the Management of Diabetic Macular Edema: The European Vitreo-Retinal Society Macular Edema Study

Table 1

Baseline demographic patient data.

	Number of cases	Mean pretreatment Va LogMAR (Snellen)	Standard deviation	Mean number of treatments
Monotherapy
Anti-VEGF only	139	0.7 (0.2)	0.41	2.13
Threshold grid	97	0.39 (0.41)	0.32	1.66
PPV-ILM	61	0.86 (0.14)	0.52	1.00
Subthreshold grid	52	0.36 (0.44)	0.25	2.35
Triamcinolone	41	0.69 (0.2)	0.40	1.08
Combination therapy
Anti-VEGF (1) + threshold grid (2)	130	0.64 (0.23)	0.40	(1) 1.85; (2) 1.44
Anti-VEGF (1) + subthreshold grid (2)	30	0.61 (0.25)	0.37	(1) 1.37; (2) 2.32
Triamcinolone (1) + threshold grid (2)	38	0.64 (0.23)	0.46	(1) 1.24; (2) 1.46
Triamcinolone (1) + anti-VEGF (2)	31	0.62 (0.24)	0.39	(1) 1.20; (2) 1.44
Triamcinolone (1) + PPV-ILM (2)	68	0.79 (0.16)	0.39	(1) 1.21; (2) 1.00

VEGF = vascular endothelial growth factor.
PPV-ILM = pars plana vitrectomy with internal limiting membrane peeling.